OncoMatch/Clinical Trials/NCT06766643
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
Is NCT06766643 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for primary liver cancer.
A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: anti-tumor treatment
No previous anti-tumor treatment
Cannot have received: anti-target tumor therapies
Previous treatment with anti-target tumor therapies
Cannot have received: upper abdominal radiotherapy
History of upper abdominal radiotherapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9, platelets ≥ 70 × 10^9, hemoglobin ≥ 80 g/L
Kidney function
serum creatinine < 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL/min
Liver function
bilirubin < 3.0 mg/dL, INR < 1.7, albumin ≥ 2.8 g/dL, AST/ALT < 6
Normal major organ functions, including blood routine tests [absolute neutrophil count (ANC) ≥ 1.5 × 10^9, platelets ≥ 70 × 10^9, hemoglobin ≥ 80 g/L], liver function tests [bilirubin < 3.0 mg/dL, international normalized ratio (INR) < 1.7, albumin ≥ 2.8 g/dL, aspartate transaminase (AST)/alanine transaminase (ALT) < 6], serum creatinine < 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify